Rabies virus-based recombinant immunocontraceptive compositions and methods of use
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 3, 2013
Grant Date -
Jul 7, 2011
app pub date -
Aug 20, 2009
filing date -
Sep 17, 2008
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Described herein are recombinant rabies viruses comprising a heterologous nucleic acid sequence encoding an immunocontraceptive protein, such as gonadotropin-releasing hormone (GnRH) or zona pellucida 3 (ZP3). The recombinant rabies viruses disclosed herein are recovered by reverse genetics, replicate efficiently, elicit rabies virus neutralizing antibodies and immunocontraceptive peptide-specific antibodies in vaccinated animals, and protect vaccinated animals against wild-type rabies virus challenge. Further provided is a method of immunizing a non-human animal against rabies virus infection and simultaneously inhibiting fertility of the animal, comprising administering an immunogenic composition comprising one or more of the recombinant rabies viruses described herein.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully